Sage Therapeutics

SAGE68

$5.51arrow_drop_down3.83%-$0.22

SAGE68

$5.51

arrow_drop_down3.83%-$0.22

Performance History

Key Stats
Open	$5.74
Prev. Close	$5.73
EPS	-5.57
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	5.74	5.74
52 Week Range	5.62	28.26

Ratios







EPS	-5.57

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Sage Therapeutics (SAGE)

Sage Therapeutics Inc. (SAGE) is a biopharmaceutical company that specializes in the development and commercialization of novel medicines to treat central nervous system disorders. The company's mission is to make a difference in the lives of people suffering from debilitating conditions such as postpartum depression, major depressive disorder, and Parkinson's disease. Through its innovative approach, Sage Therapeutics aims to provide new treatment options for patients and improve their quality of life.

Sage Therapeutics Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. The company's lead product candidate is called SAGE-547, which is being developed for the treatment of postpartum depression. This condition affects approximately one in nine women who give birth and can have a profound impact on their ability to care for themselves and their newborns.

The potential market for SAGE-547 is significant, as there are currently no approved medications specifically indicated for postpartum depression. The company has conducted clinical trials to evaluate the safety and efficacy of SAGE-547 and has reported positive results. If approved by regulatory authorities, SAGE-547 could become the first and only treatment available for postpartum depression, addressing a significant unmet medical need.

In addition to its work in postpartum depression, Sage Therapeutics is also investigating the use of SAGE-547 for the treatment of major depressive disorder and Parkinson's disease. The company believes that its innovative approach to drug development, which focuses on targeting specific receptors in the brain, has the potential to revolutionize the treatment of central nervous system disorders.

Sage Therapeutics Inc. has a market capitalization of approximately $3 billion and operates in the biotechnology industry. The company's stock (SAGE) is listed on the Nasdaq exchange and has a 52-week range of $35.73 to $92.58. The stock's day range is $89.24 to $92.58, and the trading volume is currently above average.

In conclusion, Sage Therapeutics Inc. is a biopharmaceutical company that is pioneering the development of novel medicines for central nervous system disorders. With its lead product candidate SAGE-547, the company aims to address the significant unmet medical need in postpartum depression. If successful, SAGE-547 could provide a breakthrough treatment option for millions of women worldwide. With its innovative approach and strong financial position, Sage Therapeutics Inc. is well positioned for future growth and success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Barry E. Greene
Headquarters: Cambridge
Employees: 689
Exchange: NASDAQ

Keep an eye on Sage Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Sage Therapeutics 's (SAGE) price per share?

The current price per share for Sage Therapeutics (SAGE) is $5.52. The stock has seen a price change of -$0.22 recently, indicating a -3.84% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Sage Therapeutics (SAGE)?

For Sage Therapeutics (SAGE), the 52-week high is $28.26, which is 412.14% from the current price. The 52-week low is $5.47, the current price is 0.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Sage Therapeutics (SAGE) a growth stock?

Sage Therapeutics (SAGE) has shown an average price growth of -3.55% over the past three years. It has received a score of 7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sage Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Sage Therapeutics (SAGE) stock price performance year to date (YTD)?

As of the latest data, Sage Therapeutics (SAGE) has a year-to-date price change of -75.45%. Over the past month, the stock has experienced a price change of -18.97%. Over the last three months, the change has been -32.21%. Over the past six months, the figure is -54.64%. Looking at a longer horizon, the five-year price change stands at -96.17%.

help

Is Sage Therapeutics (SAGE) a profitable company?

Sage Therapeutics (SAGE) has a net income of -$541.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -852.52% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $86.46M, although specific revenue growth data is currently not available. The gross profit is $84.3M. Operating income is noted at -$579.85M. Furthermore, the EBITDA is -$371.15M.

help

What is the market capitalization of Sage Therapeutics (SAGE)?

Sage Therapeutics (SAGE) has a market capitalization of $337.68M. The average daily trading volume is 5.55, indicating the stock's liquidity and investor engagement.

News

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

SAGE THERAPEUTICS

SECURITIES LAW VIOLATIONS

CLASS ACTION LAWSUIT

Oct 28, 2024

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit

Sage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit

SAGE THERAPEUTICS

SECURITIES CLASS ACTION

SAGE DEADLINE NOTICE: Rosen, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Sage Therapeutics (SAGE)

Keep an eye on Sage Therapeutics

Frequently Asked Questions

What is Sage Therapeutics 's (SAGE) price per share?

What is the 52-week high and low for Sage Therapeutics (SAGE)?

Is Sage Therapeutics (SAGE) a growth stock?

What is Sage Therapeutics (SAGE) stock price performance year to date (YTD)?

Is Sage Therapeutics (SAGE) a profitable company?

What is the market capitalization of Sage Therapeutics (SAGE)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level